Review

Novel routes for allergen immunotherapy: safety, efficacy and mode of action

Philippe Moingeon

Stallergenes SA, Département Scientifique, 6 rue Alexis de Tocqueville, 92160 Antony, France

Search for more papers by this author

Laurent Mascarell

* Author for correspondence

Research & Development, Stallergenes SA, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France.

Search for more papers by this author

Email the corresponding author at lmascarell@stallergenes.fr

Published Online:17 Feb 2012https://doi.org/10.2217/imt.11.171

View article

Abstract

Allergen immunotherapy is the only curative treatment of IgE-mediated type I respiratory allergies. Subcutaneous immunotherapy (SCIT) is used as a reference therapy and has transformed allergic treatments; it improves symptoms (asthma and rhinitis) as well as the quality of life of patients. SCIT requires repetitive administration and carries the risk of severe systemic adverse effects, including anaphylaxis. Sublingual immunotherapy is now a valid noninvasive alternative to SCIT, as a safe and efficacious treatment for respiratory allergies. In this article, we compare various routes of allergen immunotherapy, including SCIT and sublingual immunotherapy, as well as more exploratory routes currently under investigation (i.e., intralymphatic, epicutaneous, intranasal and oral). We discuss their respective advantages, as well as their foreseen modes of action.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

1 Noon L. Prophylactic inoculation against hay fever. Lancet2,1572–1573 (1911).▪▪ Inception of allergen therapy for treating seasonal allergic rhinitis to grass pollen.Crossref, Google Scholar
2 Canonica G, Bousquet J, Casale T et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy64,1–59 (2009).▪▪ Guidelines on the use of allergen immunotherapy in allergic respiratory diseases.Crossref, Medline, Google Scholar
3 Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.118,434–440 (2006).▪▪ Pivotal trial showing sublingual immunotherapy (SLIT) efficacy and safety.Crossref, Medline, CAS, Google Scholar
4 Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol.120,1338–1345 (2007).▪▪ Pivotal trial showing SLIT efficacy and safety.Crossref, Medline, CAS, Google Scholar
5 Ibanez MD, Kaiser F, Knecht R et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr. Allergy Immunol.18,516–522 (2007).Crossref, Medline, Google Scholar
6 Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol.121,512–518 (2008).Crossref, Medline, CAS, Google Scholar
7 Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.123,160–166 (2009).Crossref, Medline, CAS, Google Scholar
8 Didier A, Melac M, Montagut A et al. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy64,166–171 (2009).Crossref, Medline, CAS, Google Scholar
9 Horak F, Jaeger S, Worm M, Melac M, Didier A. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment. Clin. Exp. Allergy39,394–400 (2009).Crossref, Medline, CAS, Google Scholar
10 Malling HJ, Montagut A, Melac M et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin. Exp. Allergy39,387–393 (2009).Crossref, Medline, CAS, Google Scholar
11 Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol.102,558–562 (1998).Crossref, Medline, CAS, Google Scholar
12 Larche M. Specific immunotherapy. Br. Med. Bull.56,1019–1036 (2000).Crossref, Medline, CAS, Google Scholar
13 Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin. Exp. Allergy29,497–506 (1999).Crossref, Medline, CAS, Google Scholar
14 Michils A, Mairesse M, Ledent C et al. Modified antigenic reactivity of anti-phospholipase A2 IgG antibodies in patients allergic to bee venom: conversion with immunotherapy and relation to subclass expression. J. Allergy Clin. Immunol.102,118–126 (1998).Crossref, Medline, CAS, Google Scholar
15 Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy56,301–306 (2001).Crossref, Medline, CAS, Google Scholar
16 Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J. Allergy Clin. Immunol.109,251–256 (2002).Crossref, Medline, Google Scholar
17 Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy62,1335–1338 (2007).Crossref, Medline, CAS, Google Scholar
18 Maloy KJ, Erdmann I, Basch V et al. Intralymphatic immunization enhances DNA vaccination. Proc. Natl Acad. Sci. USA98,3299–3303 (2001).Crossref, Medline, CAS, Google Scholar
19 Johansen P, Haffner AC, Koch F et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur. J. Immunol.35,568–574 (2005).Crossref, Medline, CAS, Google Scholar
20 von Beust BR, Johansen P, Smith KA et al. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur. J. Immunol.35,1869–1876 (2005).Crossref, Medline, CAS, Google Scholar
21 Senti G, Johansen P, Kundig TM. Intralymphatic immunotherapy. Curr. Opin Allergy Clin. Immunol.9,537–543 (2009).Crossref, Medline, Google Scholar
22 Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA105,17908–17912 (2008).Crossref, Medline, CAS, Google Scholar
23 Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. La Presse Medicale67,2299–2301 (1959).Medline, CAS, Google Scholar
24 Werfel T. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy? J. Allergy Clin. Immunol.124,1003–1004 (2009).Crossref, Medline, Google Scholar
25 Senti G, von Moos S, Kundig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy66,798–809 (2011).Crossref, Medline, CAS, Google Scholar
26 Senti G, Graf N, Haug S et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol.124,997–1002 (2009).Crossref, Medline, CAS, Google Scholar
27 Dupont C, Kalach N, Soulaines P et al. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J. Allergy Clin. Immunol.125,1165–1167 (2010).Crossref, Medline, CAS, Google Scholar
28 Deuschl H, Johansson GO. Hyposensitization of patients with allergic rhinitis by intranasal administration of chemically modified grass pollen allergen. A pilot study. Acta Allergol.32,248–262 (1977).Crossref, Medline, CAS, Google Scholar
29 Nickelsen JA, Goldstein S, Mueller U et al. Local intranasal immunotherapy for ragweed allergic rhinitis. I. Clinical response. J. Allergy Clin. Immunol.68,33–40 (1981).Crossref, Medline, CAS, Google Scholar
30 Georgitis JW, Reisman RE, Clayton WF et al. Local intranasal immunotherapy for grass-allergic rhinitis. J. Allergy Clin. Immunol.71,71–76 (1983).Crossref, Medline, CAS, Google Scholar
31 Nickelsen JA, Georgitis JW, Mueller UR et al. Local nasal immunotherapy for ragweed-allergic rhinitis. III. A second year of treatment. Clin. Exp. Allergy13,509–519 (1983).Crossref, CAS, Google Scholar
32 Andri L, Senna GE, Betteli C et al. Local nasal immunotherapy in allergic rhinitis to Parietaria. A double-blind controlled study. Allergy47,318–323 (1992).Crossref, Medline, CAS, Google Scholar
33 Andri L, Senna G, Betteli C et al. Local nasal immunotherapy for Dermatophagoides-induced rhinitis: efficacy of a powder extract. J. Allergy Clin. Immunol.91,987–996 (1993).Crossref, Medline, CAS, Google Scholar
34 D’Amato G, Lobefalo G, Liccardi G, Cazzola M. A double-blind, placebo-controlled trial of local nasal immunotherapy in allergic rhinitis to Parietaria pollen. Clin. Exp. Allergy25,141–148 (1995).Crossref, Medline, Google Scholar
35 Andri L, Senna G. Local nasal immunotherapy. Allergy50,190 (1995).Crossref, Medline, CAS, Google Scholar
36 Andri L, Senna G, Betteli C et al. Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: a double-blind study. J. Allergy Clin. Immunol.97,34–41 (1996).Crossref, Medline, CAS, Google Scholar
37 Bellussi L, Bologna M, Di Stanislao C et al. Simplified local nasal immunotherapy in mite dust allergic rhinitis. J. Investig. Allergol. Clin. Immunol.12,42–47 (2002).Medline, CAS, Google Scholar
38 Tsai JJ, Liao EC, Tsai FH, Hsieh CC, Lee MF. The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen dermatophagoides pteronyssinus. J. Asthma46,165–170 (2009).Crossref, Medline, CAS, Google Scholar
39 Passalacqua G, Albano M, Riccio AM, Scordamaglia A, Canonica GW. Local nasal immunotherapy: experimental evidences and general considerations. Allergy52,10–16 (1997).Crossref, Medline, CAS, Google Scholar
40 Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4–5 years. J. Investig. Allergol. Clin. Immunol.13,228–231 (2003).Medline, CAS, Google Scholar
41 Egger C, Horak F, Vrtala S, Valenta R, Niederberger V. Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. J. Allergy Clin. Immunol.126,1312–1315 (2010).Crossref, Medline, CAS, Google Scholar
42 Rebien W, Puttonen E, Maasch HJ, Stix E, Wahn U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur. J. Pediatr.138,341–344 (1982).Crossref, Medline, CAS, Google Scholar
43 Taudorf E, Weeke B. Orally administered grass pollen. Allergy38,561–564 (1983).Crossref, Medline, CAS, Google Scholar
44 Mosbech H, Dreborg S, Madsen F et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy42,451–455 (1987).Crossref, Medline, CAS, Google Scholar
45 Urbanek R, Burgelin KH, Kahle S, Kuhn W, Wahn U. Oral immunotherapy with grass pollen in enterosoluble capsules. A prospective study of the clinical and immunological response. Eur. J. Pediatr.149,545–550 (1990).Crossref, Medline, CAS, Google Scholar
46 Taudorf E, Laursen LC, Lanner A et al. Oral immunotherapy in birch pollen hay fever. J. Allergy Clin. Immunol.80,153–161 (1987).Crossref, Medline, CAS, Google Scholar
47 Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double blind study. Allergy41,271–279 (1986).Crossref, Medline, CAS, Google Scholar
48 Taudorf E, Laursen L, Lanner A et al. Specific IgE, IgG, and IgA antibody response to oral immunotherapy in birch pollinosis. J. Allergy Clin. Immunol.83,589–594 (1989).Crossref, Medline, CAS, Google Scholar
49 Leng X, Fu YX, Ye ST, Duan SQ. A double-blind trial of oral immunotherapy for Artemisia pollen asthma with evaluation of bronchial response to the pollen allergen and serum-specific IgE antibody. Ann. Allergy64,27–31 (1990).Medline, CAS, Google Scholar
50 Litwin A, Flanagan M, Entis G et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J. Allergy Clin. Immunol.100,30–38 (1997).Crossref, Medline, CAS, Google Scholar
51 Giovane AL, Bardare M, Passalacqua G et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin. Exp. Allergy24,53–59 (1994).Crossref, Medline, CAS, Google Scholar
52 Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J. Allergy Clin. Immunol.121,1344–1350 (2008).Crossref, Medline, CAS, Google Scholar
53 Buchanan AD, Green TD, Jones SM et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol.119,199–205 (2007).Crossref, Medline, CAS, Google Scholar
54 Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy59,980–987 (2004).Crossref, Medline, CAS, Google Scholar
55 Meglio P, Giampietro PG, Gianni S, Galli E. Oral desensitization in children with immunoglobulin E-mediated cow’s milk allergy – follow-up at 4 yr and 8 months. Pediatr. Allergy Immunol.19,412–419 (2008).Crossref, Medline, Google Scholar
56 Staden U, Rolinck-Werninghaus C, Brewe F et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy62,1261–1269 (2007).Crossref, Medline, CAS, Google Scholar
57 Longo G, Barbi E, Berti I et al. Specific oral tolerance induction in children with very severe cow’s milk-induced reactions. J. Allergy Clin. Immunol.121,343–347 (2008).Crossref, Medline, CAS, Google Scholar
58 Skripak JM, Nash SD, Rowley H et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J. Allergy Clin. Immunol.122,1154–1160 (2008).Crossref, Medline, CAS, Google Scholar
59 Varshney P, Jones SM, Scurlock AM et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J. Allergy Clin. Immunol.127,654–660 (2011).Crossref, Medline, CAS, Google Scholar
60 Morris DL. Treatment of respiratory disease with ultra-small doses of antigens. Ann. Allergy28,494–500 (1970).Medline, CAS, Google Scholar
61 Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy54,249–260 (1999).Crossref, Medline, CAS, Google Scholar
62 La Rosa M, Ranno C, Andre C et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol.104,425–432 (1999).Crossref, Medline, CAS, Google Scholar
63 Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev.2,CD002893 (2003).Medline, Google Scholar
64 Clavel R, Bousquet J, Andre C. Clinical efficacy of sublingual-swallow immunotherapy: a double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy53,493–498 (1998).Crossref, Medline, CAS, Google Scholar
65 Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy53,662–672 (1998).Crossref, Medline, CAS, Google Scholar
66 Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol.108,S147–S334 (2001).Crossref, Medline, CAS, Google Scholar
67 Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy55,842–849 (2000).Crossref, Medline, CAS, Google Scholar
68 Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J. Allergy Clin. Immunol.115,1184–1188 (2005).Crossref, Medline, Google Scholar
69 Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy60,4–12 (2005).Crossref, Medline, CAS, Google Scholar
70 Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol. Clin. Immunol.15,9–16 (2005).Medline, CAS, Google Scholar
71 Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy61,1162–1172 (2006).Crossref, Medline, CAS, Google Scholar
72 Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol.97,141–148 (2006).Crossref, Medline, CAS, Google Scholar
73 Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr. Opin Allergy Clin. Immunol.9,168–176 (2009).Crossref, Medline, Google Scholar
74 Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma. Immunol.93,3–12 (2004).Crossref, Medline, Google Scholar
75 Pajno GB, Peroni DG, Vita D et al. Safety of sublingual immunotherapy in children with asthma. Paediatr. Drugs5,777–781 (2003).Crossref, Medline, Google Scholar
76 Mascarell L, Van Overtvelt L, Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol. Allergy Clin. North Am.26,283–306 (2006).Crossref, Medline, Google Scholar
77 Baena-Cagnani CE, Passalacqua G, Baena-Cagnani RC, Croce VH, Canonica WG. Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Curr. Opin Allergy Clin. Immunol.5,173–177 (2005).Crossref, Medline, Google Scholar
78 Fiocchi A, Pajno G, La Grutta S et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann. Allergy Asthma Immunol.95,254–258 (2005).Crossref, Medline, Google Scholar
79 Didier A, Melac M, Combebias A, Andre C. Efficacy and safety of sublingual immunotherapy grass pollen tablets in grass pollen rhinoconjonctivitis. J. Allergy Clin. Immunol.117,721 (2006).Crossref, Google Scholar
80 Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J. Allergy Clin. Immunol.118,1292–1298 (2006).Crossref, Medline, CAS, Google Scholar
81 Bussmann C, Maintz L, Hart J et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin. Exp. Allergy37,1277–1285 (2007).Crossref, Medline, CAS, Google Scholar
82 Pajno GB, Caminiti L, Vita D et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol.120,164–170 (2007).Crossref, Medline, CAS, Google Scholar
83 Calderon MA, Casale TB, Togias A et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J. Allergy Clin. Immunol.127,30–38 (2011).Crossref, Medline, Google Scholar
84 Brozek JL, Bousquet J, Baena-Cagnani CE et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol.126,466–476 (2010).Crossref, Medline, Google Scholar
85 Mondoulet L, Dioszeghy V, Vanoirbeek JA et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int. Arch. Allergy Immunol.154,299–309 (2011).Crossref, Medline, CAS, Google Scholar
86 Mondoulet L, Dioszeghy V, Ligouis M et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin. Exp. Allergy40,659–667 (2010).Crossref, Medline, CAS, Google Scholar
87 Winkler B, Hufnagl K, Spittler A et al. The role of FoxP3⁺ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy61,173–180 (2006).Crossref, Medline, CAS, Google Scholar
88 Mascarell L, Saint-Lu N, Moussu H et al. Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol.4,638–647 (2011).Crossref, Medline, CAS, Google Scholar
89 Van Overtvelt L, Moussu H, Horiot S et al. Lactic acid bacteria as adjuvants for sublingual allergy vaccines. Vaccine.28,2986–2992 (2010).Crossref, Medline, CAS, Google Scholar
90 Saint-Lu N, Tourdot S, Razafindratsita A et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy64,1003–1013 (2009).Crossref, Medline, CAS, Google Scholar
91 Lee SE, Koh YI, Kim MK et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J. Clin. Immunol.28,157–165 (2008).Crossref, Medline, CAS, Google Scholar
92 Lombardi V, Van Overtvelt L, Horiot S et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin. Exp. Allergy38,1819–1829 (2008).Medline, CAS, Google Scholar
93 Van Overtvelt L, Lombardi V, Razafindratsita A et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int. Arch. Allergy Immunol.145,152–162 (2008).Crossref, Medline, CAS, Google Scholar
94 Razafindratsita A, Saint-Lu N, Mascarell L et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J. Allergy Clin. Immunol.120,278–285 (2007).Crossref, Medline, CAS, Google Scholar
95 Hisbergues M, Magi M, Rigaux P et al.In vivo and in vitro immunomodulation of Der p 1 allergen-specific response by Lactobacillus plantarum bacteria. Clin. Exp. Allergy.37,1286–1295 (2007).Crossref, Medline, CAS, Google Scholar
96 Mascarell L, Van Overtvelt L, Lombardi V et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/Treg immune responses and enhances tolerance induction via the sublingual route. Vaccine26,108–118 (2007).Crossref, Medline, CAS, Google Scholar
97 Liu YH, Tsai JJ. Production of salivary immunoglobulin A and suppression of Dermatophagoides pteronyssinus-induced airway inflammation by local nasal immunotherapy. Int. Arch. Allergy Immunol.138,161–168 (2005).Crossref, Medline, CAS, Google Scholar
98 Hufnagl K, Focke M, Gruber F et al. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin. Exp. Allergy38,1192–1202 (2008).Crossref, Medline, CAS, Google Scholar
99 Allam JP, Duan Y, Winter J et al. Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites. Allergy66,532–539 (2011).Crossref, Medline, CAS, Google Scholar
100 Sun JB, Cuburu N, Blomquist M et al. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces FoxP3⁺CD25⁺CD4⁺ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand. J. Immunol.64,251–259 (2006).Crossref, Medline, CAS, Google Scholar
101 Sun JB, Czerkinsky C, Holmgren J. Sublingual ‘oral tolerance’ induction with antigen conjugated to cholera toxin B subunit generates regulatory T cells that induce apoptosis and depletion of effector T cells. Scand. J. Immunol.66,278–286 (2007).Crossref, Medline, CAS, Google Scholar
102 Daniel C, Repa A, Wild C et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy61,812–819 (2006).Crossref, Medline, CAS, Google Scholar
103 Mousavi T, Tajik N, Moradi M, Radjabzadeh MF. CpG immunotherapy in Chenopodium album sensitized mice: the comparison of IFN-gamma, IL-10 and IgE responses in intranasal and subcutaneous administrations. Clin. Mol. Allergy6,10 (2008).Crossref, Medline, Google Scholar
104 Liu Z, Guo H, Wu Y et al. Local nasal immunotherapy: efficacy of Dermatophagoides farinae – chitosan vaccine in murine asthma. Int. Arch. Allergy Immunol.150,221–228 (2009).Crossref, Medline, CAS, Google Scholar
105 Dioszeghy V, Mondoulet L, Dhelft V et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J. Immunol.186,5629–5637 (2011).Crossref, Medline, CAS, Google Scholar
106 Mascarell L, Lombardi V, Louise A et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4⁺ T cells. J. Allergy Clin. Immunol.122,603–609 (2008).Crossref, Medline, CAS, Google Scholar
107 Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol.13,143–157 (2006).Crossref, Medline, CAS, Google Scholar
108 Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(⁺)CD25(⁺) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med.194,629–644 (2001).Crossref, Medline, CAS, Google Scholar
109 Oida T, Zhang X, Goto M et al. CD4⁺CD25^- T cells that express latency-associated peptide on the surface suppress CD4⁺CD45RB^high-induced colitis by a TGF-beta-dependent mechanism. J. Immunol.170,2516–2522 (2003).Crossref, Medline, CAS, Google Scholar
110 Chen ML, Yan BS, Bando Y, Kuchroo VK, Weiner HL. Latency-associated peptide identifies a novel CD4⁺CD25⁺ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J. Immunol.180,7327–7337 (2008).Crossref, Medline, CAS, Google Scholar
111 Sun CM, Hall JA, Blank RB et al. Small intestine lamina propria dendritic cells promote de novo generation of FoxP3 T reg cells via retinoic acid. J. Exp. Med.204,1775–1785 (2007).Crossref, Medline, CAS, Google Scholar
112 Sun JB, Flach CF, Czerkinsky C, Holmgren J. B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol.181,8278–8287 (2008).Crossref, Medline, CAS, Google Scholar
113 Hadis U, Wahl B, Schulz O et al. Intestinal tolerance requires gut homing and expansion of FoxP3⁺ regulatory T cells in the lamina propria. Immunity34,237–246 (2011).Crossref, Medline, CAS, Google Scholar
114 Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol.121,1120–1125 (2008).▪ Early induction of IL-10 and IgG4-blocking antibodies as surrogate markers of allergen immunotherapy efficacy.Crossref, Medline, CAS, Google Scholar
115 Nickelsen JA, Goldstein S, Mueller U et al. Local intranasal immunotherapy for ragweed allergic rhinitis. II. Immunologic response. J. Allergy Clin. Immunol.68,41–45 (1981).Crossref, Medline, CAS, Google Scholar
116 Patriarca G, Nucera E, Roncallo C et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment. Pharmacol. Ther.17,459–465 (2003).Crossref, Medline, CAS, Google Scholar
117 Wachholz PA, Durham SR. Induction of ‘blocking’ IgG antibodies during immunotherapy. Clin. Exp. Allergy33,1171–1174 (2003).Crossref, Medline, CAS, Google Scholar
118 Pierson-Mullany LK, Jackola D, Blumenthal M, Rosenberg A. Altered allergen binding capacities of Amb a 1-specific IgE and IgG4 from ragweed-sensitive patients receiving immunotherapy. Ann. Allergy Asthma. Immunol.84,241–243 (2000).Crossref, Medline, CAS, Google Scholar
119 Iliopoulos O, Proud D, Adkinson NF Jr et al. Effects of immunotherapy on the early, late, and rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells. J. Allergy Clin. Immunol.87,855–866 (1991).Crossref, Medline, CAS, Google Scholar
120 Bousquet PJ, Calderon MA, Demoly P et al. The Consolidated Standards of Reporting Trials (CONSORT) statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J. Allergy Clin. Immunol.127,49–56 (2011).Crossref, Medline, Google Scholar
121 van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4⁺ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol.163,2944–2952 (1999).Medline, CAS, Google Scholar
122 van Neerven RJ, Arvidsson M, Ipsen H et al. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin. Exp. Allergy34,420–428 (2004).Crossref, Medline, CAS, Google Scholar
123 Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual FoxP3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy40,598–606 (2010).Medline, CAS, Google Scholar
124 Bahceciler NN, Arikan C, Taylor A et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int. Arch. Allergy Immunol.136,287–294 (2005).Crossref, Medline, Google Scholar
125 Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol.102,157–164 (1998).Crossref, Medline, CAS, Google Scholar
126 El Biaze M, Boniface S, Koscher V et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy58,844–853 (2003).Crossref, Medline, CAS, Google Scholar
127 Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin. Exp. Allergy28,917–920 (1998).Crossref, Medline, CAS, Google Scholar
128 Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA⁺ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol.99,254–260 (1997).Crossref, Medline, CAS, Google Scholar
129 Benjaponpitak S, Oro A, Maguire P et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J. Allergy Clin. Immunol.103,468–475 (1999).Crossref, Medline, CAS, Google Scholar
130 Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from Th2 to Th1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy27,1007–1015 (1997).Crossref, Medline, CAS, Google Scholar
131 Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4⁺ T cells from allergic individuals. J. Exp. Med.178,2123–2130 (1993).Crossref, Medline, CAS, Google Scholar
132 Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance. Clin. Exp. Allergy40,1578–1579 (2010).Crossref, Medline, CAS, Google Scholar
133 Meiler F, Zumkehr J, Klunker S et al.In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J. Exp. Med.205,2887–2898 (2008).▪ Critical role of type 1 Tregs in immune tolerance to allergens in healthy individuals.Crossref, Medline, CAS, Google Scholar
134 Robinson DS, Larche M, Durham SR. Tregs and allergic disease. J. Clin. Invest.114,1389–1397 (2004).Crossref, Medline, CAS, Google Scholar
135 Piconi S, Trabattoni D, Rainone V et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J. Immunol.185,7723–7730 (2010).Crossref, Medline, CAS, Google Scholar
136 Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal immunotherapy. Curr. Opin Allergy Clin. Immunol.9,554–557 (2009).Crossref, Medline, Google Scholar
137 Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans’ cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol.112,141–148 (2003).▪ Identification of key tolerogenic Langerhans cells involved in SLIT efficacy.Crossref, Medline, CAS, Google Scholar
138 Allam JP, Wurtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J. Allergy Clin. Immunol.126,638–645 (2010).Crossref, Medline, CAS, Google Scholar
139 Allam JP, Peng WM, Appel T et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol.121,368–374 (2008).Crossref, Medline, CAS, Google Scholar
140 Marcucci F, Sensi L, Incorvaia C et al. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy62,1475–1477 (2007).Crossref, Medline, CAS, Google Scholar
141 Allam JP, Stojanovski G, Friedrichs N et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy63,720–727 (2008).Crossref, Medline, Google Scholar
142 Mascarell L, Lombardi V, Zimmer A et al. Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4⁺ T cells. Clin. Exp. Allergy39,1910–1919 (2009).Crossref, Medline, CAS, Google Scholar
143 Valenta R. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol.2,446–453 (2002).Crossref, Medline, CAS, Google Scholar
144 Batard T, Didierlaurent A, Chabre H et al. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy. Int. Arch. Allergy Immunol.136,239–249 (2005).Crossref, Medline, CAS, Google Scholar
145 Moingeon P, Lombardi V, Saint-Lu N et al. Adjuvants and vector systems for allergy vaccines. Immunol. Allergy Clin. North Am.31,407–419 (2011).Crossref, Medline, Google Scholar
146 Senti G, Johansen P, Haug S et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a Phase I/IIa clinical trial. Clin. Exp. Allergy Immunol.39,562–570 (2009).Crossref, CAS, Google Scholar
147 Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a Phase I/IIa study. Int. Arch. Allergy Immunol.154,336–344 (2011).Crossref, Medline, CAS, Google Scholar
148 Mascarell L, Zimmer A, Van Overtvelt L, Tourdot S, Moingeon P. Induction of allergen-specific tolerance via mucosal routes. Curr. Top. Microbiol. Immunol.820,85–105 (2011).Crossref, Google Scholar

Vol. 4, No. 2

Metrics

Downloaded 178 times

History

Published online 17 February 2012

Published in print February 2012

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download